Based on current KDIGO guidelines (2024 updates), ASNC position statements, and recent peer-reviewed evidence (UpToDate 2024, NEJM 2023;389:1517–1528; Nat Rev Nephrol 2022;18:653–668)

I. Acute Interstitial Nephritis (AIN)

Definition & Pathophysiology
Acute interstitial nephritis is an immune-mediated or direct toxic injury to the renal interstitium characterized histologically by:

• Interstitial edema,
• Dense mononuclear cell infiltrates (CD4+/CD8+ T cells, macrophages),
• Variable eosinophil presence, and
• Tubular epithelial injury ranging from vacuolization to necrosis.

Importantly, interstitial fibrosis may develop within weeks if inflammation is unmitigated—this represents a key transition point toward irreversible chronic kidney disease (CKD). Animal models suggest that persistent T-cell activation and profibrotic cytokine release (e.g., TGF-β, IL-13) drive this progression (Nat Rev Nephrol 2022).

Epidemiology & Etiology

• Drug-induced AIN accounts for 60–80% of cases, with NSAIDs now surpassing β-lactams as the most frequent culprits in recent cohort studies (KDIGO 2024).
• Incidence is rising, partly due to increased exposure to proton pump inhibitors (PPIs), immune checkpoint inhibitors, and antibiotics in elderly populations.
• Latency period: Typically 7–14 days for first-time drug exposure; re-exposure may cause symptoms in <3 days.

High-Risk Medications with Clinical Nuances

Note: Drug-specific HLA associations are increasingly recognized (e.g., HLA-DQB106:02 with omeprazole-AIN), suggesting future potential for pharmacogenomic screening.

Clinical Presentation & Diagnosis

Classic triad (fever, rash, eosinophilia) occurs in only ~30% of cases (particularly in drug-induced AIN). Many patients present with atypical or subtle features, especially the elderly:

Diagnostic Workup – Stepwise Approach

1. Clinical suspicion: AKI + systemic symptoms + recent drug exposure → strongly suspect AIN.
2. Urine studies:
   • Eosinophiluria: ≥1% eosinophils in urinary sediment (sensitivity 60–75%, specificity >90%) using shallow-layer cytospin staining (not routine dipstick).
   • Elevated α1-microglobulin, β2-microglobulin, NAG enzyme—indicators of tubular damage.
3. Serum markers:
   • Eosinophilia (>500 cells/μL) in ~40% of cases (more reliable in children).
   • Elevated IgE levels (especially in NSAID/PPI-AIN).
4. Renal imaging: Ultrasound—usually normal; may show enlarged kidneys with increased echogenicity (non-specific).
5. Nuclear imaging (Gallium-67 or FDG-PET):
   • Gallium scan shows “flare” pattern in renal cortex—sensitivity ~80% but low specificity.
   • FDG-PET emerging as superior alternative with higher resolution and earlier detection (Eur J Nucl Med Mol Imaging 2023;50:1671–1680).

Gold standard: Renal biopsy—indications include:

• Persistent or progressive AKI despite drug withdrawal,
• Diagnosis uncertainty (e.g., vs. ATN, RPGN),
• Need to assess fibrosis burden for prognosis.

Histopathologic hallmarks:

• Interstitial edema and diffuse inflammatory infiltrate (T cells > macrophages > eosinophils).
• Tubulitis (lymphocytes within tubular epithelium) is highly specific for immune-mediated injury.
• Chronic changes (interstitial fibrosis, tubular atrophy) predict slower/incomplete recovery.

Management & Prognosis

Stepwise Therapeutic Algorithm

1. Immediate drug cessation – cornerstone of management; withholding the offending agent alone leads to renal recovery in ~50% within 2–4 weeks (KDIGO 2024).
2. Steroid indication: Consider early (within 2–4 weeks of symptom onset) if:
   • Severe AKI (eGFR <30 mL/min/1.73m²),
   • Persistent symptoms/signs beyond 1 week after drug withdrawal,
   • Biopsy showing significant inflammation with minimal fibrosis.
   Regimen:
   • Prednisone 0.5–1 mg/kg/day (max 40–60 mg/day) for 2–4 weeks → taper over 4–8 weeks to avoid rebound inflammation.
   • IV methylprednisolone pulse (500–1000 mg/day × 3 days) may be used in rapidly progressive cases or those with systemic vasculitic features.
   Evidence: Meta-analysis (Nephrol Dial Transplant 2022;37:847–856) shows steroids reduce time to renal recovery by ~10 days (RR 1.62, 95% CI 1.24–2.12) and lower risk of CKD progression at 1 year (OR 0.41, 95% CI 0.23–0.73).
3. Adjunctive measures:
   • Avoid nephrotoxins (e.g., contrast, NSAIDs),
   • Maintain euvolemia (avoid volume overload in oliguric AKI),
   • Correct electrolyte abnormalities (e.g., hyperkalemia).
4. Dialysis:
   • Required in ~20–30% of cases—usually transient; >85% achieve renal independence within 3 months if treated early.

Prognostic Factors

• Long-term outcomes: ~85–90% achieve full or partial renal recovery. However, up to 15% develop CKD stage ≥3 over 5 years—often linked to delayed diagnosis/treatment.

II. Chronic Interstitial Nephritis (CIN)

Definition & Pathogenesis
CIN refers to chronic inflammation, fibrosis, and tubular atrophy primarily affecting the interstitium, leading to progressive decline in GFR. Unlike AIN, fibrosis is the dominant histologic feature with relatively less active inflammation.

Etiologies Requiring Targeted Therapy

Critical Pitfall: CIN may be misclassified as “CKD of unknown etiology”—biopsy is indicated when clinical features suggest treatable causes (KDIGO 2024 Class I recommendation).

Clinical Features

• Insidious onset: Often asymptomatic until advanced CKD.
• Tubular dysfunction precedes GFR decline:
  • Concentrating defect → nocturia, polyuria
  • Distal RTA → metabolic acidosis, hypokalemia
  • Impaired Na+/K+ handling → salt-wasting, hypotension
• Late-stage: Symptoms of uremia; proteinuria is typically mild (<1 g/day) unless glomerular involvement (e.g., secondary FSGS).

Diagnostic Evaluation

• Urine: Low osmolality (<300 mOsm/kg), elevated β2-microglobulin, tubular proteinuria.
• Blood tests: Metabolic acidosis, hypokalemia, hypercalciuria; ACE in sarcoidosis.
• Imaging: Renal ultrasound—small, contracted kidneys in end-stage; DMSA scan shows segmental scarring.
• Biopsy indication: Unexplained CKD with tubular dysfunction ± systemic symptoms; essential to identify treatable etiologies.

Management Principles

1. Etiology-directed therapy:
   • Sarcoidosis: Prednisone 0.5–0.75 mg/kg/day ( taper over ≥6 months); methotrexate for maintenance.
   • Lithium-induced: Discontinue if possible; amiloride may reduce lithium uptake via ENaC inhibition.
   • Hypercalcemia: Hydration, bisphosphonates, treat underlying malignancy.
2. CKD support:
   • ACEi/ARBs: First-line for BP control and renoprotection (target BP <130/80 mmHg; KDIGO 2021). Use cautiously if bilateral renal artery stenosis or eGFR <30 mL/min.
   • SGLT2 inhibitors (e.g., dapagliflozin): Class I recommendation for CKD progression reduction regardless of diabetes status (CREDENCE, DAPA-CKD trials; NEJM 2019;381:361–372).
   • Avoid nephrotoxins rigorously.
3. Monitoring:
   • q3–6mo eGFR, urine albumin/creatinine ratio, electrolytes.

Key Takeaways for Clinical Practice

• AIN is a medical emergency: Early recognition (drug history + AKI ± systemic signs) and prompt drug withdrawal are critical.
• Biopsy remains diagnostic cornerstone—don’t hesitate in diagnostically uncertain AKI.
• Steroids improve renal recovery when used early—but avoid if contraindicated or in advanced fibrosis.
• CIN is underdiagnosed: Actively seek treatable etiologies (e.g., sarcoidosis, obstructive uropathy).
• Long-term follow-up: Even after “recovery” from AIN, monitor for CKD progression annually.

Emerging Tools: Urinary CD68+ macrophages and MCP-1 correlate with active interstitial inflammation; may guide biopsy timing in the future (Kidney Int 2023;104:592–603).

This integrated, evidence-based approach optimizes renal salvage while minimizing irreversible damage—aligning with KDIGO’s “treat-to-prevent” paradigm for glomerular and interstitial diseases.